-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Mentari Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga·11/10/2026 09:58:06
Listen to the news
Stifel analyst Paul Matteis initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.